| Literature DB >> 32940811 |
David Bauer1,2, Anna Farthofer1, David Chromy1,2,3, Benedikt Simbrunner1,2, Lisa Steininger1,2, Caroline Schmidbauer1,2,4, Teresa Binter1,2, Michael Trauner1, Mattias Mandorfer1,2, Ralf Schmidt5, Florian Mayer5, Heidemarie Holzmann6, Robert Strassl5, Thomas Reiberger7,8,9.
Abstract
To explore the epidemiology and clinical course of hepatitis A virus (HAV) infections at the Vienna General Hospital. We retrospectively identified patients who were tested positive for HAV-IgM at the Vienna General Hospital form Q1/2008 to Q3/2018. Our definition of severe HAV infection was AST and/or ALT > 5 × above the upper limit of normal (ULN); and liver dysfunction as (i) hepatic encephalopathy or ammonia > 100 μmol/L, (ii) coagulopathy with INR > 1.5, or (iii) jaundice with bilirubin > 5 mg/dL. A total of 578 HAV-IgM (+) were identified, including 31 (5.4%) and 38 (6.6%) without and with liver dysfunction, respectively. A proportional increase in severe HAV cases with and without liver dysfunction occurred in 2016/2017 with (21.5% (vs. 8.0% in the years before; p < 0.001). Thirty-seven (53.6%) patients with severe HAV were hospitalized, 6 (9%) required ICU support, and one patient received liver transplantation within 30 days. Patients with severe HAV and liver dysfunction were more often male (60.5 vs. 43.1%, p = 0.055) and younger (31.5 vs. 63 years, p < 0.001) as compared with other HAV-IgM (+) cases. The observed increase of severe HAV infections in Vienna in 2017 among young males, coincided with a multinational HAV outbreak among MSM. Our data suggests a higher likelihood of severe courses of hepatitis A in MSM. Vaccination against HAV should be recommended for risk groups.Entities:
Keywords: Austria; Hepatitis A; Hepatitis A epidemiology; Viral hepatitis A
Mesh:
Year: 2020 PMID: 32940811 PMCID: PMC7817601 DOI: 10.1007/s10096-020-04028-x
Source DB: PubMed Journal: Eur J Clin Microbiol Infect Dis ISSN: 0934-9723 Impact factor: 3.267